Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial

Journal:

Nature Communications

Published:

2025-07-21

DOI:

10.1038/s41467-025-61691-4

Affiliations:

23

Authors:

40

Go to article

Institutions	Authors	Share
NIHR Leicester Biomedical Research Centre, United Kingdom (UK)	11.500000 11.500000	0.29
NIHR Southampton Biomedical Research Centre, United Kingdom (UK)	7.000000	0.18
University of Leicester, United Kingdom (UK)	5.000000	0.13
University Hospitals of Leicester NHS Trust (UHL), United Kingdom (UK)	2.000000	0.05
University of Liverpool, United Kingdom (UK)	1.000000	0.03
Wythenshawe Hospital, MFT, United Kingdom (UK)	1.000000	0.03
Queen's University Belfast (QUB), United Kingdom (UK)	1.000000	0.03
Sheffield Teaching Hospitals NHS Foundation Trust, United Kingdom (UK)	1.000000	0.03
Beatson West of Scotland Cancer Centre (BWoSCC), United Kingdom (UK)	1.000000	0.03
Mavis Nye Foundation, United Kingdom (UK)	1.000000	0.03
Queen Mary University of London (QMUL), United Kingdom (UK)	1.000000	0.03
The York Hospital, York and Scarborough Teaching Hospitals NHS Foundation Trust, United Kingdom (UK)	1.000000	0.03
Mesothelioma UK, United Kingdom (UK)	1.000000	0.03
Harry Perkins Institute of Medical Research (HPIMR), Australia	1.000000	0.03
MRC Toxicology Unit, University of Cambridge, United Kingdom (UK)	1.000000	0.03
The Institute of Cancer Research (ICR), United Kingdom (UK)	1.000000	0.03
Novogene Co., Ltd., China	0.500000	0.01
King Faisal Specialist Hospital and Research Centre (KFSH&RC), Saudi Arabia	0.500000	0.01
University of Tripoli (UT), Libya	0.500000	0.01
Singleton Hospital, NHS Wales, United Kingdom (UK)	0.500000	0.01
Morriston Hospital, NHS Wales, United Kingdom (UK)	0.500000	0.01

Interested in Oncology and Carcinogenesis?